前列腺癌超大分割盆腔预防性照射的肠袋剂量学参数
研究纳入59例接受25 Gy/5次每周分割盆腔预防性照射的前列腺癌患者,回顾性勾画肠袋并分析剂量学参数与胃肠道毒性及肠道生活质量的关系。未发现肠袋剂量学参数与急晚期2级及以上胃肠道毒性或肠道生活质量临床重要变化相关,但基于实际治疗计划提出肠袋剂量约束建议。
要点
- 59例患者中急性2级胃肠道毒性7例(12%),晚期2级12例(20%),无3级及以上毒性。
- 未发现肠袋剂量学参数与急晚期2级及以上胃肠道毒性或肠道生活质量变化相关。
- 基于实际治疗计划提出肠袋约束:V20 Gy最佳<320 cc、强制<380 cc;V24 Gy最佳<150 cc、强制<200 cc等。
核心结论
- 未发现肠袋剂量学参数与胃肠道毒性或肠道生活质量相关,但基于实际治疗计划提出了超大分割盆腔预防性照射的肠袋剂量约束建议。
研究设计与样本
- 纳入SATURN和5STAR试验中59例接受盆腔预防性照射的前列腺癌患者,处方剂量为25 Gy分5次每周分割。
- 回顾性按RTOG指南勾画肠袋,前瞻性收集至试验后5年的胃肠道毒性和肠道生活质量数据。
- 从实际治疗计划提取肠袋剂量学参数,采用逻辑回归分析其与毒性和生活质量的关系。
主要发现
- 59例中急性2级胃肠道毒性7例(12%),晚期2级12例(20%),无3级及以上胃肠道毒性。
- 55例中急性肠道生活质量临床重要变化21例(38%),晚期10例(18%)。
- 未发现肠袋剂量学参数与急性/晚期2级及以上胃肠道毒性或肠道生活质量临床重要变化相关。
关键数值与推荐
- 基于实际治疗计划的肠袋剂量约束:V20 Gy最佳<320 cc、强制<380 cc;V24 Gy最佳<150 cc、强制<200 cc。
- V25 Gy最佳<80 cc、强制<100 cc;最大点剂量最佳<27 Gy、强制<35 Gy。
临床怎么用
- 可将所提出的肠袋剂量约束(V20 Gy、V24 Gy、V25 Gy及最大点剂量)作为超大分割盆腔预防性照射的参考。
- 肠袋剂量学参数与毒性未显示相关性,临床应用时需结合个体情况谨慎解读。
局限性
- 回顾性勾画肠袋,样本量较小(59例),可能限制统计效能。
- 未发现剂量学参数与毒性的关联,所提约束基于实际治疗计划的中位数和四分位距上限,尚需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Most prostate SABR trials with pelvic elective nodal irradiation (ENI) applied dose constraints to individual bowel loops. There is no evidence-based data to guide bowel bag dose constraints in ultrahypofractionated ENI for prostate cancer. We aimed to correlate bowel bag dosimetric parameters with gastrointestinal toxicities and bowel quality of life (QOL). METHODS AND MATERIALS: We included 59 men enrolled in the SATURN and 5STAR trials. The prescribed dose of ENI was 25 Gy in 5 fractions delivered in weekly fractionation. The bowel bag was retrospectively contoured as per the Radiation Therapy Oncology Group guidelines. Gastrointestinal toxicities and bowel QOL data were prospectively collected up to 5 years after the trial using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4 and the Expanded Prostate Cancer Index questionnaire. Dosimetric parameters for the bowel bag based on delivered treatment plans were extracted. Logistic regressions were performed to identify dosimetric parameters associated with gastrointestinal toxicities and bowel QOL. RESULTS: Of the 59 men included in this analysis, 7 of 59 men (12%) and 12 of 59 men (20%) had acute and late grade 2 gastrointestinal toxicities, respectively, with no grade 3+ gastrointestinal toxicities. There were 21 of 55 men (38%) and 10 of 55 men (18%) who had minimal clinically important changes in acute and late bowel QOL. No bowel bag dosimetric parameters were identified to be associated with acute/late grade 2+ gastrointestinal toxicities or minimal clinically important changes in bowel QOL. Based on bowel bag dosimetry of the delivered treatment plans, we propose bowel bag dose constraints for ultrahypofractionated ENI, applying the median and IQR upper limit as optimal and mandatory constraints: V20 Gy (optimal <320 cc; mandatory <380 cc), V24 Gy (optimal <150 cc; mandatory <200 cc), V25 Gy (optimal <80 cc; mandatory <100 cc), and maximum point dose (optimal <27 Gy; mandatory <35 Gy). CONCLUSIONS: Using individual patient data from prospective trials, we did not identify bowel bag dosimetric parameters associated with gastrointestinal toxicities and bowel QOL; however, this provided us with data that suggested dose constraints for future practice.
引用
- Ong WL, Davidson M, Wronski M, et al. Bowel Bag Dosimetric Parameters for Ultrahypofractionated Pelvic Elective Nodal Irradiation in Prostate Cancer. Int J Radiat Oncol Biol Phys. 2025. PMID: 40819809. doi:10.1016/j.ijrobp.2025.08.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。